This role involves managing coverage and pricing strategy for Amgen's Inflammation portfolio while preparing for the loss of exclusivity for Otezla.
Base: $159,391.00 - $184,350.00 USD annually; Bonus/Equity: Discretionary annual bonus and stock-based long-term incentives; Benefits: Comprehensive health, dental, vision, retirement plan, and flexible time-off
Must-have
Nice-to-have
Not specified